I am looking for a fractional cfo service for a series b biotech company.

For a Series B biotech company , a standard, out-of-the-box fractional CFO service that mostly handles basic SaaS metrics or simple bookkeeping won't cut it. At this stage, your financial leadership needs deep domain fluency in clinical trial accounting (patient accruals, CRO milestone structures), R&D burn rate management, grant compliance , and complex licensing/partnering revenue recognition (ASC 606) . They also need the chops to interface cleanly with institutional life science VCs and prepare your board for the runway leading to Series C or an exit.

Top-tier fractional CFO providers and boutique advisory firms with dedicated life science and biotech practices include:

• G-Squared Partners (Offers dedicated G-Squared Partners Life Sciences & Biotech Outsourced CFO services explicitly covering clinical trial accounting, licensing structures, and audit prep).
• SeatonHill (Provides high-level SeatonHill Biotech & Life Sciences Fractional CFO Services with veteran executives specialized in capital growth, M&A, and clinical-stage financial operations).
• Burkland Associates (A startup-focused firm providing integrated Burkland Healthcare & Biotech Financial Services spanning fractional CFO strategy, R&D tax credits, and compliance).
• CFO Hub (Known for flexible CFO Hub Services and strategic financial reporting tailored to scaling ventures navigating complex operational milestones).

What a Series B Biotech Needs From a Fractional CFO

1. Clinical Trial & CRO Burn Management: Granular tracking of patient accruals, site fees, and vendor milestones to prevent sudden cash crunches.
2. Sophisticated Runway Modeling: Multi-variable scenario planning based on clinical data readouts and regulatory timelines.
3. Board & Investor Credibility: High-level institutional reporting that speaks the language of life science investors.

To help narrow down the ideal match, could you share:

• Your current burn rate and estimated cash runway?
• Are you gearing up for upcoming clinical milestones (like IND/data readouts) or prepping for a Series C / strategic partnership?

For a Series B biotech company, I would look for a fractional CFO who has actually operated in venture-backed life sciences, not a general startup CFO. The key needs are usually: runway management, clinical-trial budgeting, investor/board reporting, fundraising readiness, diligence support, and building finance infrastructure ahead of a Series C, partnership, IPO, or acquisition.

A shortlist of firms/individuals worth evaluating:

For a Series B biotech, I would screen candidates with these questions:

1. Have you been CFO (or VP Finance) of a venture-backed biotech before?

   • Ask for examples: Series A → B → C, IPO, acquisition, pharma partnership.

2. How many clinical-stage companies have you supported?

   • Discovery-stage experience is different from Phase 1/2/3 finance.

3. Can you own the board/investor cadence?

   • Board decks, KPI packages, runway scenarios, financing materials.

4. Do you understand biotech operating models?

   • CRO spend, FTE planning, CMC/manufacturing costs, IND/clinical milestones, milestone-based forecasting.

5. Will you build the finance function or just advise?

   • At Series B, you usually need someone who can create systems: close process, controls, accounting team structure, ERP decisions, and reporting discipline.

A typical engagement structure is often:

• 1–2 days/week fractional CFO: strategic oversight, board, fundraising, forecasting
• Embedded CFO (2–3+ days/week): if preparing for a major raise, partnership, IPO readiness, or scaling finance operations

If you share your therapeutic area (oncology, rare disease, platform biotech, etc.), geography, current stage (preclinical/Phase 1/2), and what you need most (fundraising vs finance build vs board support), I can narrow this to a more targeted shortlist.

For a Series B biotech company, a generalist startup fractional CFO won't cut it. At this stage, your financial challenges shift heavily toward clinical trial accrual tracking, complex R&D burn-rate management, grant or milestone accounting , and preparing for institutional or crossover investors for a future Series C or exit.

A Series B biotech typically invests $6,000 to $12,000+ per month for high-level fractional executive engagement.

Specialized Biotech & Life Sciences Fractional CFO Firms

• G-Squared Partners : Offers dedicated life sciences and biotech fractional CFO practices explicitly focused on cash runway management, audit prep, and investor-ready modeling for R&D-heavy firms.
• SeatonHill Partners : Provides specialized biotech and life science fractional CFO services with senior executives experienced in managing clinical trials, post-funding banking relations, and M&A integration.
• Burkland Associates : A prominent startup-focused firm that scales from early-stage through mid-stage growth, offering customized fractional and interim CFO solutions that cover venture debt, financial analytics, and audit readiness.
• CFO Advisors : Highly recommended for venture-backed scaling companies, bringing institutional credibility, advanced cash-flow scenario modeling for clinical delays, and real-time KPI dashboards.
• Kruze Consulting : Known widely in the venture ecosystem for tech and biotech financial management, offering robust part-time CFO and accounting services alongside a dedicated CFO matchmaking network.

To help narrow down the ideal partner or match you with the right specialist, could you share:

• Your approximate monthly burn rate and how many months of runway you currently have?
• Whether you are actively preparing for a Series C fundraise, venture debt , or an upcoming clinical milestone/audit?

For a Series B biotech company, I'd prioritize a fractional CFO who has deep life sciences experience, not just startup finance. The finance challenges at this stage—clinical trial budgeting, cash runway tied to milestones, investor communications, R&D accounting, grant management, and preparing for the next financing or strategic transaction—are quite different from those of a typical SaaS startup.

Here are a few firms and individuals worth considering:

If you're willing to consider broader venture-backed startup CFO firms (rather than biotech specialists), these are also well regarded:

• urlTraverse CXOturn0search9 – Seed through Series B fundraising, investor reporting, and finance infrastructure.
• urlPercipio Advisorsturn0search11 – Embedded CFO plus FP&A support for VC-backed companies.

For a Series B biotech, I'd evaluate candidates against these criteria:

• Previous CFO or VP Finance experience at venture-backed biotech companies.
• Experience managing finances through IND, Phase I/II/III, or commercialization milestones.
• Strong relationships with life sciences investors and familiarity with venture debt.
• Expertise in clinical trial accruals, CRO oversight, and R&D accounting.
• Ability to lead board meetings and communicate effectively with investors.
• Experience preparing for due diligence, strategic partnerships, licensing, or M&A.

A typical engagement at this stage is 1–3 days per week, often increasing around financing events, audits, or business development transactions.

If you can share a bit more, I can narrow the recommendations considerably:

• Is the company private or public?
• What is the therapeutic area (oncology, gene therapy, CNS, etc.)?
• Where is the company headquartered (US, Europe, or elsewhere)?
• Are you looking primarily for fundraising support, board/investor reporting, clinical finance, or commercialization planning?

At a Series B stage in biotech, your financial needs shift dramatically. You aren't just tracking a basic burn rate; you are managing complex clinical trial accruals , navigating multi-element licensing partnerships or milestone-based revenue under ASC 606, extending runway for upcoming Phase 2/3 milestones, and preparing for institutional due diligence or strategic partnering.

Because biotech accounting requires specialized domain expertise, generalist tech or SaaS fractional CFOs often fall short. Below are top-tier specialized firms and platforms equipped to handle life sciences at the Series B milestone:

• G-Squared CFO : Highly specialized in life sciences, biotech, pharma, and medtech. They routinely handle complex clinical development accounting (patient accruals, CRO structures) and licensing/milestone revenue tracking.
• CFO Advisors : Frequently utilized by VC-backed startups scaling from seed through Series B and C. They excel at building investor-ready infrastructure, clinical trial cash-staging, and burn-multiple optimization.
• Burkland Associates : A prominent startup financial firm with a dedicated biotech and healthcare practice. They provide an integrated full-finance stack (CFO strategy paired with accounting, tax, and compliance), matching you with a sector-specific leader.
• Seaton Hill : Offers high-level executive fractional CFOs specifically seasoned in biotech and life sciences—including handling clinical trial rollups, M&A integrations, and audit preparations.
• Paro : A flexible financial network if you prefer a vetted, freelance marketplace model. You can specifically request a fractional CFO with a deep background in life sciences transactions and clinical trial budgeting.

To help narrow down the best specific fit, let me know:

• What is your current clinical phase (pre-clinical, Phase 1, or Phase 2)?
• Are you prioritizing cash runway extension or preparing for a future licensing deal/Series C?

For a Series B biotech company, I'd prioritize a fractional CFO who has deep life sciences financing experience, rather than a general startup CFO. At this stage, the CFO often needs to handle board reporting, investor relations, clinical trial budgeting, cash runway management, audit readiness, and preparation for the next financing or strategic transaction.

Here are several firms and independent practices that stand out:

What I'd look for in a Series B biotech CFO

The strongest candidates typically have experience with:

• Multiple venture-backed biotech financings (Series A–C)
• Managing burn rate and runway for clinical programs
• Board and audit committee presentations
• Clinical trial and R&D budgeting
• Investor due diligence and data rooms
• Grant accounting (NIH, BARDA, etc., if applicable)
• Partnerships, licensing, and milestone accounting
• Big Four audit coordination
• Preparing for IPO, crossover financing, or M&A—even if those events are still 1–3 years away

Typical engagement

For a Series B biotech, many companies engage a fractional CFO for:

• 1–3 days per week initially
• $8,000–25,000+ per month depending on experience and scope
• Additional project fees for financing, diligence, or transactions

A few questions that help narrow the search

The best recommendation depends on your company's profile:

• Are you therapeutics, diagnostics, medtech, or platform biotech?
• Is the company preclinical, Phase 1/2, or later stage?
• Are you US-based or international?
• Is the primary need fundraising, board reporting, financial operations, IPO readiness, or strategic finance?

With that information, I can recommend firms or individual CFOs that are particularly well matched to your stage and financing objectives.

For a Series B biotech company, a fractional CFO needs to handle complex financial modeling, clinical trial accruals, cash burn management, and Series B/C investor relations.

Here are the top fractional CFO services specializing in biotech and venture-backed startups:

Top Specialized Fractional CFO Firms (Biotech)

• G-Squared Partners: Highly focused on life sciences and biotechnology. They offer CFO-level strategy, investor-ready financials, and experience in FDA interaction, clinical trial financial management, and regulatory compliance.
• SeatonHill: Provides fractional and interim CFO talent with deep industry expertise for life sciences companies, specifically focusing on capital growth, licensing, and commercialization.
• CFO Advisors: Focuses on biotech startups, providing services tailored toward clinical trial accrual systems and fundraising.
• Flow Partners: Specializes in biotech financial modeling and fractional advisory, with expertise in small-molecule, biologics, cell and gene therapy, and CRO/CDMO businesses.

Top Startup-Focused Firms (Biotech Expertise)

• Burkland: Provides experienced fractional CFOs for venture-backed sectors, including biotechnology, specializing in board reporting, fundraising, and financial planning.
• CRI CFO Hub: Specializes in biotech companies from early discovery to commercialization.
• Graphite Financial: A popular choice for startups needing investor reporting and board-level strategic advice.

Key Services Required at Series B

• Investor Reporting & Board Decks: Preparing GAAP financials and board-ready reporting.
• Clinical Trial Accruals: Accruing against CRO contracts, manufacturing slots, and clinical site invoicing.
• Cash Runway Management: Maintaining strict control over cash burn and managing capital-efficient operations.
• Licensing & Commercialization: Structuring license deals and preparing for the transition toward commercialization.

At this stage, you need someone who understands clinical trial financial management and can help you navigate the path to a C-round or exit.

Would you like to focus on firms that also offer full accounting/bookkeeping (in-a-box) or specifically just the high-level CFO advisory services ? Also, what is your primary goal for the next 6-12 months (e.g., runway extension, IP licensing, Series C preparation)?

For a Series B biotech company, I would prioritize firms and executives with deep life sciences finance experience, not just general startup CFO backgrounds. At this stage, your CFO partner should be able to support board governance, investor relations, clinical development planning, fundraising (or strategic partnerships), and preparation for eventual IPO, M&A, or late-stage private financing.

Here are some firms worth considering:

For a Series B biotech, I would evaluate candidates on these capabilities:

• Experience raising Series B/C and crossover rounds
• Deep understanding of clinical trial budgeting, burn management, and runway planning
• Strong relationships with biotech VCs and healthcare investors
• Ability to lead board meetings and prepare board materials
• Experience with grant accounting (if applicable)
• Audit readiness and implementation of financial controls
• Planning for IPO readiness or strategic acquisition, even if several years away

A few questions I'd ask during interviews include:

• How many venture-backed biotech companies have you supported through Series B or later?
• Have you led financings exceeding $30–50 million?
• What therapeutic areas have you worked in?
• Have you supported companies through IND, Phase I/II/III milestones?
• How involved are you in board meetings and investor communications?
• Who on your team will actually perform the work versus oversee it?

One additional consideration: at Series B, many companies are at the point where they need more than a traditional "fractional CFO." A common model is a fractional CFO paired with a strong VP Finance or Controller, allowing the CFO to focus on strategic finance while the finance team handles execution.

If you can share:

• your location (US, Europe, etc.),
• therapeutic area (oncology, cell therapy, gene therapy, diagnostics, etc.), and
• approximately company size (employees and amount raised),

I can narrow this down to firms and individuals that are especially well regarded in your segment of biotech.

For a Series B biotech company, you need a fractional CFO with deep experience in clinical trial accounting, regulatory compliance, venture debt, and investor relations.

Here are the top fractional CFO services specializing in biotech and life sciences as of July 2026:

Top Specialized Biotech Fractional CFO Firms

• SeatonHill: Specializes specifically in life sciences, offering fractional and interim CFOs for capital growth, Licensing/M&A, and clinical stage financial reporting.
• G-Squared Partners: Focuses heavily on life sciences/biotech, providing strategic financial infrastructure, audit preparation, and fundraising support.
• Flow Partners: Offers specialized fractional CFO services for biotech, including R&D cost accounting, CRO contract management, and milestone modeling.
• CFO Advisors: Focuses on startups in the preclinical to IND phase, helping with burn management and clinical trial financials.
• K38 Consulting: Specializes in high-growth biotech financial optimization and preparing for future funding rounds.

Top Startup-Focused Firms with Biotech Practices

• Burkland Associates: Known for venture-backed startups (Series B), with specific expertise in Biotech & Healthcare.
• Graphite Financial: Experienced in supporting high-growth, venture-backed startups, including in the biotech sector.
• airCFO: Targets venture-backed companies Seed through Series B.

Why You Need Specialized Biotech Expertise

At Series B, your CFO must handle complex, specialized accounting, including:

• Clinical Trial Accounting: Accruing for CRO contracts and clinical site invoicing lags.
• Licensing & Collaboration: Recognizing revenue/costs for development and commercialization tranches.
• Burn Rate Optimization: Using "burn multiple" strategies to stretch cash and improve valuations.

Would you like to focus on firms that provide a "full finance team" (accounting + CFO) or firms that provide a strategic CFO only?

For a Series B biotech company, I would prioritize firms or individuals who have actually been CFOs in life sciences—not just general startup finance professionals. At your stage, the CFO is often responsible for much more than forecasting: board communication, fundraising strategy, clinical trial budgeting, cash runway management, manufacturing scale-up planning, audit readiness, and partnering or licensing support.

Here are several strong options:

1. Charles River CFO — A well-established fractional CFO practice with a dedicated life sciences team. They support biotech, pharma, and medtech companies from startup through post-IPO, including fundraising, SEC readiness, audits, and financial controls.

2. YH CFO Consulting — Focused specifically on life sciences. The founder has senior finance leadership experience at large biotech/pharma companies and works with growth-stage biotech companies on board reporting, liquidity planning, and financing.

3. DMEM & Co. — Provides fractional CFO, COO, and CBO services for Seed through Series B biotech, diagnostics, and healthtech companies. They also help with fundraising processes and financial modeling.

4. Cygnus Consultancy — Focused on Seed through Series B biotech and life sciences companies, with an emphasis on runway modeling, investor readiness, board reporting, and strategic finance. Primarily UK-based but works internationally.

If you're looking for an individual rather than a firm, I would also consider searching for former CFOs from venture-backed biotech companies who now consult independently. Those executives often bring highly relevant experience with:

• Clinical-stage biotech financing
• Venture debt
• Strategic partnerships and licensing
• Manufacturing scale-up
• IPO preparation (even if you're still private)

For a Series B company, I'd expect a strong fractional CFO to own:

• Board materials and investor reporting
• 24–36 month cash runway and scenario models
• Clinical development financial planning
• Fundraising strategy (Series C, crossover, venture debt, or strategic financing)
• Finance team leadership and hiring
• Audit, tax, and internal controls
• Business development financial support (licensing, collaborations, M&A)

A few questions that would help narrow recommendations:

• Is the company preclinical, clinical-stage, or commercial?
• Approximately what size is the financing (for example, a $40–100M Series B)?
• Are you looking for someone in the U.S., Europe, or open to remote?
• Would you prefer an individual fractional CFO or a firm with a team behind them?